{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:52:56Z","timestamp":1788817976884,"version":"build-2803163510"},"reference-count":33,"publisher":"S. Karger AG","issue":"7","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"abstract":"<jats:p>Introduction: The regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL), yet many patients relapse. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has shown promise in trials. This study investigates the real-world efficacy and safety of Pola-R-CHP versus R-CHOP. Methods: We retrospectively analyzed 505 DLBCL patients treated at Peking Union Medical College Hospital between January 2011 and March 2025. Thirty-six patients received Pola-R-CHP; 36 matched R-CHOP patients were selected using 1:1 propensity score matching based on age, sex, subtype, stage, and IPI. Outcomes included interim and end-of-treatment response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Results: Post-matching, 72 patients were included. Pola-R-CHP achieved higher interim complete response (CR) (72.2% vs. 63.9%, p = 0.035) and objective response rate (ORR) (100.0% vs. 83.3%, p = 0.011). At the end of treatment, CR was further improved (88.9% vs. 63.9%, p = 0.007), and ORR remained superior (100.0% vs. 86.1%, p = 0.020). At a median follow-up of 13.3 months (range, 1.1\u2013141.9 months), 1 death and 2 progressions occurred in the Pola-R-CHP group compared with 9 deaths and 9 progressions in the R-CHOP group. Median OS and PFS were not reached in either cohort. At 12 months, the estimated OS was 97% for Pola-R-CHP and 94% for R-CHOP (p = 0.825), while the estimated PFS was 86% and 94%, respectively. This represented a numerical but not statistically significant difference (p = 0.457), likely reflecting the immature survival data and limited number of events at the time of analysis, rather than a true efficacy difference. Neutropenia was the most frequent AE (69.4%) and showed comparable severity between groups, while grades \u22653 AEs were numerically less frequent with Pola-R-CHP (8.3% vs. 13.9%, p = 0.453). Conclusion: Pola-R-CHP achieved higher interim and end-of-treatment response rates than R-CHOP with a comparable safety profile. However, survival outcomes remain immature, and given the small matched sample size (n = 72), these findings should be interpreted cautiously and confirmed in larger prospective studies.<\/jats:p>","DOI":"10.1159\/000549477","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:01:43Z","timestamp":1763658103000},"page":"759-771","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study"],"prefix":"10.1159","volume":"104","author":[{"given":"Ziqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ni","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huacong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2027612"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3202"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.001"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27151"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100750"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1800638"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0675"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001294"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19295"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S326632"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61040-4"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70122-0"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159976"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071929"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014707"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00925"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06526-4"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00059-5"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017734"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014907"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06619-0"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70017"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00572-7"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000549477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:23:59Z","timestamp":1783009439000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000549477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000549477","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}